Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants

Journal of Clinical Pharmacology

Volumn 51, Issue 4, 2011, Pages 561-574

  Bavisotto, Linda M ^a   Ellis, David J ^b   Milner, Peter G ^b   Combs, Daniel L ^c   Irwin, Ian ^b   Canafax, Daniel M ^b  

^a CHARLES RIVER LABORATORIES   (United States)

^b ARYx Therapeutics   (United States)

^c Combs Consulting Services ^*  (United States)

Author keywords

CYP2C9; CYP3A4; Drug interaction; Fluconazole; Pharmacokinetics; Tecarfarin (ATI 5923); Vitamin K antagonists; Vitamin K epoxide reductase inhibitors; Warfarin

Indexed keywords

ANTIVITAMIN K; ATI 5900; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUCONAZOLE; PHYTOMENADIONE; TECARFARIN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HEMATURIA; HUMAN; MALE; METABOLITE; NORMAL HUMAN; PYURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ARYL HYDROCARBON HYDROXYLASES; BENZOATES; COUMARINS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; FLUCONAZOLE; HUMANS; MALE; NAD(P)H DEHYDROGENASE (QUINONE); WARFARIN;

EID: 79953804258     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010370588     Document Type: Article

References (25)

1. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Int Med. 2005;165:1095-1106. (Pubitemid 40720733)
2. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005;45: 127-132. (Pubitemid 40490435)
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133(suppl):160S-198S.
4. Warfarin sodium [package insert]. New York: Bristol Myers Squibb Company;2008.
5. Choppin A, Irwin I, Lach L, et al. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. Br J Pharmacol. 2009;158:1536-1547.
6. FDA Guidance for Industry - In Vivo Drug Metabolism/Drug Interaction Studies: Study Design, Data Analysis, and Recommendations for Dosing and Labeling, CDER and CBER, November 1999. Updated September 2006 as draft guidance: FDA Draft Guidance for Industry - Drug Interaction Studies - Study Design, Data Analysis and Implications for Dosing and Labeling, CDER and CBER. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM072119.pdf. Both accessed August 18, 2009.
7. Fluconazole [package insert]. New York: Pfizer, Inc; 2004.
8. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole: I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos. 1996;24:414-421.
9. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole: II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos. 1996;24:422-428.
10. Kunze KL, Trager WF. Warfarin-fluconazole: III. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos. 1996;24:429-435.
11. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennesy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for GI bleeding. Clin Pharmacol Ther. 2008;84:581-588.
12. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf. 2005;14:755-767. (Pubitemid 41684468)
13. Allison EJ Jr, McKinney TJ, Langenberg JN. Spinal epidural haematoma as a result of warfarin/fluconazole drug interaction. Eur J Emerg Med. 2002;9:175-177.
14. Mootha VV, Schluter ML, Das A. Intraocular hemorrhages due to warfarin fluconazole drug interaction in a patient with presumed Candida endophthalmitis. Arch Ophthalmol. 2002;120:94-95. (Pubitemid 34721371)
15. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000;38:111-118.
16. Algbengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf. 1998;18:83-97. (Pubitemid 28080742)
17. Gericke KR. Possible interaction between warfarin and fluconazole. J Hum Pharmacol Drug Ther. 1993;13:508-509. (Pubitemid 23301976)
18. Seaton TL, Celum CL, Black DJ. Possible potentiation of warfarin by fluconazole. DICP Ann Pharmacother. 1990;24:1177-1178.
19. Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med. 1993;153:102-104. (Pubitemid 23043375)
20. Limdi NA, Beasley TM, Crowley MR, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008;9:1445-1458.
21. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008;83: 312-321.
22. Zhu Y, Shennan M, Reynolds KR, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1630 G>A) and CYP2C9 genotypes. Clin Chem. 2007;53:1199-1205. (Pubitemid 47020974)
23. D'Angelo A, Della Valle P, Crippa L, Fattorini A, Pattarini E, D'Angelo SV. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica. 2002;87:1074-1080. (Pubitemid 35192220)
24. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:68-75. (Pubitemid 29053154)
25. Mahe I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled randomized study. Haematologica. 2006;91:1621-1627. (Pubitemid 46032959)